Msd Polska
- Company typePrivate
- Founded1991
- HeadquartersWarsaw, Poland
- Headcount251–500
- GTM typeB2B
- OfferingHardware or Manufacturing
What Msd Polska does
MSD Polska Sp. z o.o. is the Polish operating subsidiary of Merck & Co., Inc. (NYSE: MRK), known globally as MSD outside the United States and Canada. Established in Poland in 1991, the company develops and supplies innovative human medicines and vaccines with therapeutic emphasis on oncology, immuno-oncology, novel vaccine development, and antibiotic research targeting antibiotic-resistant bacteria. It also operates the MSD Animal Health line for veterinary pharmaceuticals in Poland. Headquartered in Warsaw at Ul. Chłodna 51, MSD Polska employs approximately 800 people as of December 2025.
The company runs an integrated operating stack that includes a wholly-owned distribution subsidiary, MSD Dystrybucja Sp. z o.o., and dedicated digital platforms such as msddlalekarzy.pl for physicians and hpv.pl for patient HPV vaccination education. MSD Polska conducts clinical research and data management in Poland and operates the Warsaw Health Innovation Hub, an innovation and talent initiative that includes the MedConnect internship program in partnership with the University of Warsaw, the Medical Research Agency (Agencja Badań Medycznych), and Polish pharmaceutical universities.
Commercially, MSD Polska pursues an enterprise field sales motion targeting hospitals, clinics, pharmacies, and healthcare institutions via medical representatives, supplemented by webinars, email, and professional portals. The company adheres to the INFARMA Good Practices Code and has been recognized with the Etyczna Firma (2025, 2026) and Orzeł Zdrowia (2025) awards. As a wholly-owned subsidiary of a publicly traded parent, standalone Polish revenue is not disclosed; capital allocation, R&D, and product strategy flow from Merck & Co. headquarters in Rahway, New Jersey.
Msd Polska firmographics
Firmographics- Name
- Msd Polska
- Legal name
- MSD Polska Sp. z o.o.
- Website
- https://msd.pl
- Company type
- Private
- Founded year
- 1991
- Operating status
- Operating
- Headcount range
- 251–500 employees
- Ownership category
- akta.pro rank
Msd Polska industry classification
Industry- Product category
- Prescription Pharmaceuticals
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412), Scientific Research and Development Services (5417)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
- akta.pro primary industry
- Vaccine Clinical Development & Regulatory Affairs (HLAIAEAM)
- akta.pro secondary industries
- Veterinary Vaccines (Biologics) (HLAMAEAL), Veterinary Vaccines (HLAIAEAH), Clinical Development & Regulatory for Vaccines (trials, pharmacovigilance, lot release) (HLAAAEAK)
Keywords
Where Msd Polska is headquartered
LocationHeadquarters
- HQ city
- Warsaw
- HQ country
- Poland
- HQ region
- Europe
Offices1 record
Markets served
Msd Polska business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Supply Chain, Marketing or Sales, Operations, Infrastructure
Revenue model
- Pharmaceutical Products: Sale of prescription pharmaceutical products including innovative medicines for oncology, vaccines, and other therapeutic areas. The company invests more than one-quarter of global turnover in R&D.
- Vaccines: Development and sale of vaccines for human health.
- Animal Health Products: MSD Animal Health division provides veterinary pharmaceutical products.
Go-to-market motion1 record
Distribution channels3 records
Marketing channels7 records
Msd Polska product offering
Product offeringCore offering
MSD Polska develops, supplies, and distributes prescription human pharmaceuticals and vaccines covering therapeutic areas including oncology, vaccines, and infectious diseases, alongside a separate MSD Animal Health line of veterinary pharmaceutical products. The subsidiary also conducts clinical research and data management activities within Poland, drawing on the parent Merck & Co., Inc.'s global biopharmaceutical R&D platform.
Product overview
MSD Polska is a biopharmaceutical company operating as part of the global Merck & Co. conglomerate (known as MSD outside the US and Canada). The company offers a portfolio of innovative medicines and vaccines for human health, alongside MSD Animal Health for veterinary pharmaceuticals. The organizational structure includes MSD Polska Sp. z o.o. (core pharmaceutical operations) and MSD Polska Dystrybucja Sp. z o.o. (distribution subsidiary). The company also operates specialized digital platforms including msddlalekarzy.pl (for physicians) and hpv.pl (patient education), with additional initiatives like the MedConnect internship program conducted through Warsaw Health Innovation Hub.
Differentiator
Problem solved
Functional benefit
Brands
- MSD Animal Health: Animal health division of MSD operating in Poland
- MSD for Mothers
- MSD Dystrybucja
- Warsaw Health Innovation Hub
Products and services
- MSD Polska Human Health prescription pharmaceuticals Innovative human medicines and vaccines covering therapeutic areas including oncology, vaccines, and infectious diseases, supplied to hospitals, clinics, and pharmacies in Poland through MSD Polska's sales force and distribution subsidiary.
- MSD Animal Health veterinary pharmaceuticals Veterinary pharmaceutical products offered to veterinarians and animal health providers in Poland under the MSD Animal Health brand.
- Clinical research and data management services Biopharmaceutical clinical trial operations and data management conducted in Poland, supporting the parent group's R&D pipeline across oncology, vaccines, and antibiotics.
- MSD Dystrybucja pharmaceutical wholesale distribution Wholesale distribution of MSD Polska's branded prescription pharmaceutical products to pharmacies, hospitals, and other healthcare customers across Poland, operated through the dedicated subsidiary MSD Dystrybucja Sp. z o.o.
Quantifiable outcome
- Over 130 years contributing to medical progress
Companies that use Msd Polska
Customer profileNamed customers2 records
Segments2 records
Ideal customer profiles2 records
Msd Polska technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Msd Polska partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core and minor.
- Uniwersytet Warszawski (University of Warsaw)coreCollaboration between University of Warsaw and MSD Polska for public health initiatives. This partnership focuses on joint efforts to advance healthcare in Poland.
- Warsaw Health Innovation HubcoreMSD Polska organizes programs including the MedConnect internship program under the Warsaw Health Innovation Hub initiative, fostering innovation in healthcare.
- Agencja Badań Medycznych (Medical Research Agency)coreThe Medical Research Agency provides patronage for the MedConnect internship program. The agency supports the development of future healthcare leaders.
- Polish Pharmaceutical UniversitiescoreCollaboration with pharmaceutical faculties of Polish universities for the MedConnect internship program. Students from these institutions are selected for internships at MSD Polska.
- INFARMAminorMSD Polska adheres to the Good Practices Code (Kodeks Dobrych Praktyk) published by INFARMA, the Polish employers' association of innovative pharmaceutical industry.
Scale indicators4 records
Recent moves5 records
Expansion highlights4 records
Msd Polska competitors and assessment
Company assessmentDirect peers
- AbbVie Poland: Polish subsidiary of AbbVie, focused on innovative therapeutics in immunology, oncology, and neuroscience. Comparable to MSD Polska as a multinational pharma subsidiary commercializing innovative specialty medicines in Poland.
- Sanofi Poland: Polish subsidiary of Sanofi. Comparable as a multinational pharma subsidiary operating in vaccines, specialty care, and animal health (through Merial/Boehringer Ingelheim Animal Health) in the Polish market.
- Bayer Poland: Polish subsidiary of Bayer, with both pharmaceutical and animal health (Animal Health) divisions. Comparable to MSD Polska across pharma and animal health product lines and clinical research operations in Poland.
- Johnson & Johnson Poland: Polish subsidiary of J&J, a global pharma and medical devices leader. Comparable to MSD Polska as a peer multinational pharma subsidiary with overlapping therapeutic areas including oncology and immunology in Poland.
- AstraZeneca Poland: Polish subsidiary of AstraZeneca. Comparable to MSD Polska as a multinational pharma subsidiary with strong presence in oncology, vaccines, and respiratory therapies, conducting clinical trials and commercial operations in Poland.
- Roche Polska: Polish subsidiary of Roche, a global leader in oncology and diagnostics. Directly comparable as a multinational pharma subsidiary operating innovative oncology therapies and clinical research in Poland.
- GSK Poland: Polish operations of GSK. Highly comparable given GSK's leadership in vaccines (a core area of MSD Polska) alongside specialty pharmaceuticals, with a similar subsidiary structure handling clinical research and commercial sales in Poland.
- Pfizer Polska: Polish subsidiary of Pfizer, one of the world's largest biopharmaceutical companies. Directly comparable to MSD Polska as a multinational pharma subsidiary operating R&D, clinical trials, and commercial sales across human vaccines, oncology, and other innovative therapies in the Polish market.
- Eli Lilly Poland: Polish subsidiary of Eli Lilly, a global pharmaceutical company with strong oncology and diabetes franchises. Comparable as a peer multinational pharma subsidiary with innovative-medicines focus and clinical research activity in Poland.
- Novartis Poland: Polish operations of Novartis, a global pharmaceutical leader. Comparable to MSD Polska as a peer multinational pharma subsidiary in Poland with overlapping presence in innovative medicines, oncology, and clinical research.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks4 records
Key highlights6 records
Customer concentration
Msd Polska social profiles
Digital presenceMsd Polska financial estimates
Financial estimateRevenue estimate
Valuation estimate
Msd Polska leadership team
Management profileNumber of profiles
Msd Polska subsidiaries and ownership
Company hierarchySubsidiaries1 record
Msd Polska funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Msd Polska M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Msd Polska
What does Msd Polska do?
MSD Polska develops, supplies, and distributes prescription human pharmaceuticals and vaccines covering therapeutic areas including oncology, vaccines, and infectious diseases, alongside a separate MSD Animal Health line of veterinary pharmaceutical products. The subsidiary also conducts clinical research and data management activities within Poland, drawing on the parent Merck & Co., Inc.'s global biopharmaceutical R&D platform.
Is Msd Polska a public or private company?
Msd Polska is a private company. It is classified as corporate owned and is currently operating.
When was Msd Polska founded?
Msd Polska was founded in 1991. It employs 251 to 500 people.
Where is Msd Polska based?
Msd Polska is headquartered in Warsaw, Poland, in the Europe region.
How does Msd Polska make money?
Three revenue lines are on record. Pharmaceutical Products are the primary driver. The others are vaccines and animal Health Products.
Who are Msd Polska's main competitors?
Direct peers on record are AbbVie Poland, Sanofi Poland, Bayer Poland, Johnson & Johnson Poland, AstraZeneca Poland, Roche Polska, GSK Poland, Pfizer Polska, Eli Lilly Poland and Novartis Poland.
Does Msd Polska have an API?
No public API is recorded for Msd Polska.
What industry is Msd Polska in?
Msd Polska's product category is Prescription Pharmaceuticals. Its primary akta.pro industry code is HLAIAEAM, Vaccine Clinical Development & Regulatory Affairs, with a secondary code of HLAMAEAL, Veterinary Vaccines (Biologics). Its NAICS code is 325414 and its SIC code is 2836.